• Conflicts of interest
    This Preface forms part of a supplement sponsored by GlaxoSmithKline. AL is a member of the Advisory Board of GSK Sweden which generates reimbursement for lectures less than once per year. He has no other conflicts of interest. KL has, during the last 5 years, on one or more occasion served on an advisory board and/or served as speaker and/or participated in education arranged by AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, MSD, Nycomed and Pfizer. He has also received unrestricted research grants from Boehringer Ingelheim, GlaxoSmithKline and AstraZeneca during the last 5 years

No abstract is available for this article.